Krensavage Asset Management, LLC - ENANTA PHARMACEUTICALS INC ownership

ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 132 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.88 and the average weighting 0.0%.

Quarter-by-quarter ownership
Krensavage Asset Management, LLC ownership history of ENANTA PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$8,211
-44.2%
735,103
+6.9%
3.02%
-35.2%
Q2 2023$14,715
-39.7%
687,613
+14.0%
4.66%
-37.1%
Q1 2023$24,397
-11.8%
603,301
+1.4%
7.41%
-13.3%
Q4 2022$27,671
-99.9%
594,818
+0.9%
8.55%
-12.2%
Q3 2022$30,570,000
+3.5%
589,360
-5.7%
9.73%
-0.3%
Q2 2022$29,533,000
-24.4%
624,768
+13.8%
9.76%
-27.5%
Q1 2022$39,066,000
-7.4%
548,828
-2.7%
13.46%
-8.0%
Q4 2021$42,184,000
-20.7%
564,102
-39.8%
14.63%
-12.4%
Q3 2021$53,218,000
+28.7%
936,777
-0.3%
16.69%
+18.9%
Q2 2021$41,354,000
-2.8%
939,650
+8.9%
14.04%
-4.7%
Q1 2021$42,556,000
+17.7%
862,848
+0.5%
14.73%
+39.5%
Q4 2020$36,156,000
-4.3%
858,811
+4.1%
10.56%
-12.2%
Q3 2020$37,784,000
-1.4%
825,329
+8.2%
12.03%
+15.4%
Q2 2020$38,315,000
+6.4%
763,103
+9.0%
10.42%
-10.0%
Q1 2020$36,017,000
+19.1%
700,318
+43.1%
11.58%
+12.3%
Q4 2019$30,234,000
+0.9%
489,385
-1.9%
10.32%
-10.3%
Q3 2019$29,972,000
-25.9%
498,874
+4.0%
11.51%
-12.4%
Q2 2019$40,467,000
-11.0%
479,576
+0.7%
13.13%
+6.9%
Q1 2019$45,472,000
+20.0%
476,042
-11.0%
12.29%
-3.9%
Q4 2018$37,882,000
-13.3%
534,825
+4.6%
12.79%
+13.9%
Q3 2018$43,686,000
-27.4%
511,186
-1.5%
11.23%
-26.9%
Q2 2018$60,156,000
+0.5%
519,035
-29.8%
15.36%
+5.8%
Q1 2018$59,852,000
+17.7%
739,738
-14.7%
14.52%
-8.4%
Q4 2017$50,862,000
+7.2%
866,770
-14.5%
15.85%
+7.2%
Q3 2017$47,448,000
+19.3%
1,013,847
-8.2%
14.79%
+22.5%
Q2 2017$39,758,000
+17.5%
1,104,992
+0.6%
12.07%
+10.6%
Q1 2017$33,835,000
-4.3%
1,098,524
+4.1%
10.91%
-14.0%
Q4 2016$35,367,000
+32.9%
1,055,719
+5.6%
12.68%
+31.9%
Q3 2016$26,603,000
+33.0%
999,741
+10.2%
9.61%
+33.4%
Q2 2016$19,998,000
-22.8%
906,930
+2.8%
7.20%
-22.5%
Q1 2016$25,920,000
-10.6%
882,529
+0.5%
9.30%
+0.5%
Q4 2015$29,006,000
+9.9%
878,446
+20.3%
9.26%
-3.1%
Q3 2015$26,393,000
-17.0%
730,308
+3.3%
9.55%
-20.4%
Q2 2015$31,804,000
+145.0%
706,908
+66.7%
12.00%
+102.9%
Q1 2015$12,983,000424,0165.91%
Other shareholders
ENANTA PHARMACEUTICALS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Krensavage Asset Management, LLC 858,811$36,156,00010.56%
Fairmount Funds Management LLC 150,433$6,333,0002.26%
ARMISTICE CAPITAL, LLC 1,356,000$57,088,0001.94%
FARALLON CAPITAL MANAGEMENT LLC 1,775,000$74,728,0000.45%
Virtus ETF Advisers LLC 14,321$603,0000.25%
Granahan Investment Management 231,071$9,728,0000.22%
JACOBS LEVY EQUITY MANAGEMENT, INC 248,320$10,454,0000.09%
ACADIAN ASSET MANAGEMENT LLC 467,514$19,684,0000.08%
VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. 126$5,0000.08%
AIGEN INVESTMENT MANAGEMENT, LP 12,854$541,0000.07%
View complete list of ENANTA PHARMACEUTICALS INC shareholders